Stock Track | BEIGENE Soars 5.11% Intraday on Stellar Q1 Earnings with 178-Fold Net Profit Surge

Stock Track05-07

BEIGENE's stock price surged 5.11% during intraday trading on Thursday, reflecting strong investor optimism following the release of the company's exceptional first-quarter financial results.

The biotechnology company reported a decisive turnaround to profitability, with net profit skyrocketing 178 times year-over-year to $227 million. Global revenue reached approximately $1.513 billion, representing a 35% increase compared to the same period last year. The performance was driven by robust sales growth of its core oncology products, Brukinsa (zanubrutinib) and Tislelizumab.

BEIGENE also reported significantly improved operating metrics, with adjusted operating profit rising 197% year-over-year to about $414 million and free cash flow increasing 14.03 times to $161 million. The company's raised full-year revenue and profit guidance further bolstered market confidence in its continued growth trajectory and global expansion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1156897696?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 09:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156897696","market":"hk","top_or_hot":-1,"title":"Stock Track | BEIGENE Soars 5.11% Intraday on Stellar Q1 Earnings with 178-Fold Net Profit Surge","media":"Stock Track","content":"<p>BEIGENE's stock price surged 5.11% during intraday trading on Thursday, reflecting strong investor optimism following the release of the company's exceptional first-quarter financial results.</p><p>The biotechnology company reported a decisive turnaround to profitability, with net profit skyrocketing 178 times year-over-year to $227 million. Global revenue reached approximately $1.513 billion, representing a 35% increase compared to the same period last year. The performance was driven by robust sales growth of its core oncology products, Brukinsa (zanubrutinib) and Tislelizumab.</p><p>BEIGENE also reported significantly improved operating metrics, with adjusted operating profit rising 197% year-over-year to about $414 million and free cash flow increasing 14.03 times to $161 million. The company's raised full-year revenue and profit guidance further bolstered market confidence in its continued growth trajectory and global expansion.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BEIGENE Soars 5.11% Intraday on Stellar Q1 Earnings with 178-Fold Net Profit Surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BEIGENE Soars 5.11% Intraday on Stellar Q1 Earnings with 178-Fold Net Profit Surge\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-07 09:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BEIGENE's stock price surged 5.11% during intraday trading on Thursday, reflecting strong investor optimism following the release of the company's exceptional first-quarter financial results.</p><p>The biotechnology company reported a decisive turnaround to profitability, with net profit skyrocketing 178 times year-over-year to $227 million. Global revenue reached approximately $1.513 billion, representing a 35% increase compared to the same period last year. The performance was driven by robust sales growth of its core oncology products, Brukinsa (zanubrutinib) and Tislelizumab.</p><p>BEIGENE also reported significantly improved operating metrics, with adjusted operating profit rising 197% year-over-year to about $414 million and free cash flow increasing 14.03 times to $161 million. The company's raised full-year revenue and profit guidance further bolstered market confidence in its continued growth trajectory and global expansion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1156897696","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156897696","pubTimestamp":1778117823,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BEIGENE's stock price surged 5.11% during intraday trading on Thursday, reflecting strong investor optimism following the release of the company's exceptional first-quarter financial results.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"个股追踪|Q1盈利亮眼百济神州盘中大涨5.11%净利大涨178倍","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"BEIGENE's stock price surged 5.11% during intraday trading on Thursday, reflecting strong investor optimism following the release of the company's exceptional first-quarter financial results.The biotechnology company reported a decisive turnaround to profitability, with net profit skyrocketing 178 times year-over-year to $227 million. Global revenue reached approximately $1.513 billion, representing a 35% increase compared to the same period last year. The performance was driven by robust sales growth of its core oncology products, Brukinsa (zanubrutinib) and Tislelizumab.BEIGENE also reported significantly improved operating metrics, with adjusted operating profit rising 197% year-over-year to about $414 million and free cash flow increasing 14.03 times to $161 million. The company's raised full-year revenue and profit guidance further bolstered market confidence in its continued growth trajectory and global expansion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156897696","isCrawlerRequest":true}